切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2019, Vol. 08 ›› Issue (06) : 553 -559. doi: 10.3877/cma.j.issn.2095-3224.2019.06.003

所属专题: 文献

论著

左右半结肠癌与Programmed Death-1信号通路
夏金红1, 顾晋1,()   
  1. 1. 100142 北京大学肿瘤医院胃肠外科三病区
  • 收稿日期:2019-05-25 出版日期:2019-12-25
  • 通信作者: 顾晋
  • 基金资助:
    北京市科委2017年首特项目(No.Z171100001017087)

Left and right sided colon cancer and programmed death-1 signaling pathway

Jinhong Xia1, Jin Gu1,()   

  1. 1. Department of Gastrointestinal Surgery III, Peking University Cancer Hospital & Institute, Beijing 100142, China
  • Received:2019-05-25 Published:2019-12-25
  • Corresponding author: Jin Gu
  • About author:
    Corresponding author: Gu Jin, Email:
引用本文:

夏金红, 顾晋. 左右半结肠癌与Programmed Death-1信号通路[J/OL]. 中华结直肠疾病电子杂志, 2019, 08(06): 553-559.

Jinhong Xia, Jin Gu. Left and right sided colon cancer and programmed death-1 signaling pathway[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(06): 553-559.

目的

探讨程序性杀伤因子1(PD1)信号通路对左、右半结肠癌预后的影响以及在左、右半结肠癌差异中所起到的作用。

方法

采用数据分析等手段分析左右半结肠癌的差异基因,分析PD1信号通路主要的PD1(PDCD1),PDL1(CD274),PDL2(PDCD1L2)在左右半结肠癌中的表达和预后差异,并采用免疫组化方法对数据分析结果进行验证。

结果

TCGA数据分析结果显示,左、右半结肠癌差异基因富集于免疫相关信号通路,其中包括PD1信号通路。PDCD1,CD274,PDCD1L2在右半肠癌的表达量显著高于左半肠癌。Kaplan-Meier生存分析显示,右半结肠癌总体生存率(OS)差于左半结肠癌,在PDCD1,CD274,PDCD1L2高表达组,右半结肠癌总体生存率差于左半结肠癌(P<0.05)。免疫组化结果显示PD1,PDL1在左、右半结肠癌中的蛋白表达与TCGA数据分析具有相同的结果,Kaplan-Meier生存分析结果显示PDL1的蛋白表达影响结肠癌的预后,表达量越高总体生存率越低。

结论

PD1/PDL1信号通路的表达差异影响左、右半结肠癌的预后。

Objective

To investigate the effect of PD1/PDL1 pathway on the prognosis of left and right sided colon cancer and the role of PD1/PDL1 signaling pathway in the difference between left and right sided colon cancer.

Methods

The differential genes of left and right sided colon cancer were analyzed by data analysis. The expression and prognosis of PD1 (PDCD1), PDL1 (CD274), PDL2 (PDCD1L2) in left and right sided colon cancer were analyzed. The results of data analysis were verified by immunohistochemical method.

Results

TCGA data analysis showed that differentially expressed genes in left and right sided colon cancer were enriched in immune-related signaling pathways, including PD1 signaling pathway. The expression of PDCD1, CD274 and PDCD1L2 in right sided colon cancer was significantly higher than that in left sided colon cancer. Kaplan-Meier survival analysis showed that the overall survival rate (OS) of right sided colon cancer was worse than that of left sided colon cancer. In the high expression groups of PDCD1, CD274 and PDCD1L2, the overall survival rate of right sided colon cancer was worse than that of left sided colon cancer (P<0.05). Immunohistochemical results showed that the protein expression of PD1 and PDL1 in left and right colon cancers had the same results as TCGA data analysis. Kaplan-Meier survival analysis showed that the protein expression of PDL1 affects the prognosis of colon cancer, and the higher the overall expression The lower the survival rate.

Conclusion

The differential expression of PD1/PDL1 signaling pathway affects the prognosis of left and right colon cancer.

表1 263例结直肠癌患者的临床病理特征
图1 2 529个左、右半结肠癌差异基因reactome通路分析
图2 PDCD1,CD274,PDCD1L2在左、右半结肠癌中的表达差异。2A:PDCD1,CD274,PDCD1L2在RCC中表达高于LCC;2B:PDCD1,CD274,PDCD1L2在各亚部位肠癌的表达
图3 PDCD1,CD274,PDCD1L2在左、右半结肠癌中的生存分析。3A~3C:PDCD1,CD274,PDCD1L2在高表达时,才有RCC预后差于LCC;3D:在整体CRC患者中,RCC预后差于LCC
图4 PD1,PDL1在左、右半肠癌中的免疫组化结果。4A:PD1在左右半结肠癌中的表达免疫组化结果,在RCC中的表达高于LCC,P=0.007;4B:PDL1在左右半结肠癌中的表达免疫组化结果,在RCC中的表达高于LCC,P=0.0044
图5 PDL2在左、右半结肠癌中的免疫组化结果及Kaplan-Meier生存分析。5A:PDL2在左、右半结肠癌中的免疫组化结果,P=0.054;5B:根据免疫组化结果,PD1,PDL1,PDL2的Kaplan-Meier生存分析结果
[1]
Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011 [J]. Chin J Cancer Res, 2015, 27 (1): 2-12.
[2]
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CA Cancer J Clin, 2013, 63 (1): 11-30.
[3]
Chen W, Zheng R, Zeng H, et al. The incidence and mortality of major cancers in China, 2012 [J]. Chinese Journal of Cancer, 2016, 35 (1): 73.
[4]
Bufill JA. Colorectal cancer: evidence for distinct geNETsic categories based on proximal or distal tumor location [J]. Ann Intern Med, 1990, 113 (10): 779-788.
[5]
Glebov OK, Rodriguez LM, KenNETsh N, et al. Distinguishing right from left colon by the pattern of gene expression [J]. Cancer Epidemiol Biomarkers Prev, 2003, 12 (8): 755-762.
[6]
Gatot I, Chikman B, Shapira Z, et al. A comparative study of the pathological characteristics of right sided versus left sided colon cancer [J]. Harefuah, 2018, 157(5): 292-295.
[7]
Song K, Zhao W, Wang W, et al. Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer [J]. Cancer Sci, 2018, 109 (6): 1939-1948.
[8]
Frank B, Rainer K, Frank M, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival [J]. Diseases of the Colon & Rectum, 2010, 53 (1): 57-64.
[9]
Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy [J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2013, 31 (29): 3664-3672.
[10]
Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials [J]. JAMA Oncol, 2017, 3(2): 194-201.
[11]
Láng I, Köhne CH, Folprecht G, et al. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin [J]. European Journal of Cancer, 2013, 49 (2): 439-448.
[12]
Hoos A. Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations [J]. Nat Rev Drug Discov, 2016, 15(4): 235-247.
[13]
Bufill JA. Colorectal cancer: evidence for distinct geNETsic categories based on proximal or distal tumor location [J]. Ann Intern Med, 1990, 113(10): 779-788.
[14]
Grasso CS, Giannakis M, Wells DK, et al. GeNETsic mechanisms of immune evasion in colorectal cancer [J]. Cancer Discov, 2018, 8 (6): 730-749.
[15]
Maj T, Wang W, Crespo J, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor [J]. Nature Immunology, 2017, 18 (12): 1332-1341.
[16]
Ji D, Yi H, Zhang D, et al. Somatic mutations and immune alternation in rectal cancer following neoadjuvant chemoradiotherapy [J]. Cancer Immunol Res, 2018, 6 (11): 1401-1416.
[17]
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition [J]. Nat Rev Immunol, 2013, 13 (4): 227-242.
[18]
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion [J]. Nat Med, 1999, 5(12): 1365-1369.
[19]
Herbst RS, Soria JC, KowaNETsz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients [J]. Nature, 2014, 515(7528): 563-567.
[20]
Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy [J]. Nat Rev Cancer, 2017, 17(5): 286-301.
[21]
Asaoka Y, Ijichi H, Koike K. PD-1 blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 373 (20): 1979.
[1] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[2] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[3] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要